PodParley PodParley
PodParley
MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review episode artwork

EPISODE · Feb 6, 2026 · 15 MIN

MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review

from MPR Weekly Dose

Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film formulation of sildenafil is approved; and the FDA accepts the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer.

Episode metadata supplied by the publisher feed · Published Feb 6, 2026

Embed this episode

Ready to play

MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review

0:00 15:05

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 15 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on February 6, 2026.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!